Eric Dobmeier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ProfoundBio secures $112m to advance ADC portfolio for cancer

ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.

Andrew lamEnoch kariukiBaiteng zhaoEric dobmeierT rowe price associatesAlly bridge groupNextech investPrice associatesJanus henderson investorsLilly asia ventures

Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B

Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Mablink bioscienceEric dobmeierErin lavelleEli lillyEnoch kariukiAndrew lamDaiichi sankyoMerck coBristol myers squibbWith big pharmasLilly asia venturesLifesci venture partnersRally bridgeBig pharmaMyers squibb

ProfoundBio Raises $112M in Series B Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Lynn yangAndrew lamEric dobmeierErin lavelleBaiteng zhaoEnoch kariukiJosh jinT rowe price associates incAlly bridge groupNextech investPrice associatesJanus henderson investorsSurveyor capitalLogos capitalOctagon capitalPiper heartland healthcare capital

ProfoundBio raises $112M to support clinical-stage oncology pipeline

ProfoundBio raises $112M to support clinical-stage oncology pipeline
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

South koreaXiao shangEric dobmeierAndrew lamEnoch kariukiBaiteng zhaoAlly bridge groupLengo therapeuticsChinook therapeuticsTae hanNextech investRowe priceJanus henderson investors

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

SEATTLE, July 28, 2023 Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today.

Noopur liffickEric dobmeierVlado perkovicUniversity of new south walesGlobenewswire incInvestor relations corporate communications media contactChinook therapeutics incExchange commissionInvestor relations corporate communicationsNew south walesAbout chinook therapeuticsDefinitive proxy statementCurrent reportsAnnual reportQuarterly reportsSecurities act